News

A three-arm clinical trial of the SAMBA program showed that screening for and tailoring to individuals' asthma needs improves their condition management.

A new study of long-term data demonstrates that infliximab and golimumab are both effective, safe treatments for symptoms of ankylosing spondylitis.

FDA has announced the approval of liraglutide injections for treatment of type 2 diabetes among pediatric patients.

Interim results at 24 weeks show that 75.3% of patients treated with tildrakizumab achieved a 20% improvement compared to 50.6% with placebo.

The new approval allows for easier access to MRIs and direct audio streaming from Android devices.

In the phase 3b/4 ORAL Shift study, tofacitinib monotherapy was shown to be comparable to tofacitinib with methotrexate.

A new study of AbbVie’s original JAK1-selective inhibitor indicates that it outdoes adalimumab without sacrificing safety in rheumatoid arthritis treatment.

Patients with rheumatoid arthritis receiving combination treatment were more likely to reach ACR20, ACR50, and ACR70 than those receiving methotrexate monotherapy.

The new study indicated that administration of a bisphosphonate before denosumab treatment, rather than at discontinuation, was far more effective at preventing rebound.

Assorted trials and a long-term exposure study of 3770 patients with rheumatoid arthritis further demonstrate baricitinib’s previously recorded safety profile.

A FUTURE 5 trial and MAXIMIZE trial demonstrate that Cosentyx frequently stops radiographic progression and lessens axial manifestations, respectively.

Ixekizumab (Talz) was significantly more likely to both reduce disease activity by ≥50% and achieve complete skin clearance than adalimumab (Humira).

The ACP's guideline committee chair discusses the thought process that went into their own update on clinical standards of guidance.

Less than half of US adults with either HBV or HCV infection are aware of their condition, and even among those aware, few receive appropriate treatment.

Kaiser Permanente Northern California’s study shows that the pertussis vaccine weakens as time passes after a patient's most recent vaccination.

Up to 77% of the increased CVD risk associated with preeclampsia and gestational hypertension is associated with conventional risk factors like BMI and blood pressure.

Experimental drug lemborexant underwent several phase 3 studies presented at the annual SLEEP 2019 meeting.

Results from the phase 3 IMMhance study show that of patients who reached sPGA 0 at week 28, 73% maintained skin clearance at week 94.

A survey of nurses at an academic medical center found that 49% averaged less than 7 hours of sleep per night, compared to the national figure of 28%.

The American College of Physicians (ACP) released a paper detailing their methods for creating clinical guidelines and guidance statements.

Contrary to earlier research, investigators found that medical cannabis laws do not reduce deaths caused by opioid overdoses.

Patients who self-referred themselves to a hospital for suicidal and/or self-harming actions did not improve more than patients who received standard treatment apart from hospitalization.

The IB-Stim device uses electrical pulses to stimulate cranial nerves and reduce pain associated with irritable bowel syndrome.

Children exposed in utero to valproate were most affected, but exposure to 3 other monotherapies were also associated with behavioral issues.

A new study debunks preceding fears that direct-acting antivirals increase the likelihood of adverse events for patients with the hepatitis C virus.

The estrogen-free pill allows for a 24-hour missed pill window while maintaining efficacy in preventing pregnancy.

Investigators found that expansion states had a median of 4.3 fewer deaths per 100,000 residents than nonexpansion states.

A new study shows that loss of phosphodiesterase, not just dopamine, indicates a worsening of motor symptoms in patients with Parkinson disease.

Patients who received the implant in addition to the surgery showed more positive results than the control group in a randomized, single-masked study.

Amarin announced the FDA had granted their sNDA for icosapent ethyl to reduce residual CV risk in patients with statin-managed LDL-C cholesterol.